Source: BioSpace

Leap Therapeutics: Leap Therapeutics Reports Third Quarter 2020 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2020 . Leap Third Quarter Highlights: First patient dosed in Phase 2a study of Leap's anti-Dickkopf-1 (DKK1) antibo

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Chris Mirabelli's photo - CEO of Leap Therapeutics


Chris Mirabelli

CEO Approval Rating


Leap Therapeutics researches, develops and commercializes monoclonal antibodies that enable immune system to identify and attack cancer cells. Read more